HR Execs on the Move

Medivation

www.medivation.com

 
Medivation Inc., which is now a part of Pfizer, Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation`s goal is to transform the treatment of these diseases and offer hope to critically ill patients and their families. With the approval of Xtandi (enzalutamide) capsules in late August 2012 and the product launch immediately following, Medivation is continuing to build and develop a world-class workforce to take the company to the next strategic level. Medivation was founded in 2004 by a group of experienced professionals with ...
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.medivation.com
  • 525 Market Street 36th Floor
    San Francisco, CA USA 94105
  • Phone: 415.543.3470

Executives

Name Title Contact Details
Tracy Porter
Director - Organizational and Talent Development Profile
Inverleith Fruci
Sr Director, Human Resources Profile

Similar Companies

Meta Materials

Meta Materials Inc. (META®), is an advanced materials and nanotechnology company. It develops new products and technologies using innovative sustainable science. Advanced materials can improve everyday products that surround us, making them smarter and more sustainable. META`s technology platforms enable global brands to develop new products to improve performance for customers in aerospace and defense, consumer electronics, 5G communications, batteries, authentication, automotive and clean energy.

Inscripta, Inc

Inscripta is a gene-editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.

Yumanity

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company`s proprietary platforms have already identified one potential new target for treating Parkinson`s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer`s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.

Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Arcxis Biotechnologies Inc

Arcxis Biotechnologies Inc is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.